Mobile Menu Close

SkyCell completes product portfolio with new frozen container for -20°C transport

At SkyCell, we are committed to innovating and refining our products to ensure we are always offering our highest level of safety to clients. Because of this, we have developed the new 1500F, the eighth container in our robust product suite that now includes solutions for all temperature ranges. The 1500F, which maintains a steady temperature of  -15°C to -25°C for more than 120 hours, allows pharma companies to protect high value medicine, vaccines, and APIs while optimising supply chains using data to predict and control risk. Further, the new 1500F maximises aircraft capacity and will enable between 2 and 3 million vials to be transported in a single aircraft

This container, built on SkyCell’s platform approach, is a game-changer due to its strong performance and lightweight design (only 470kg). The efficient design also leads to a reduction of CO2 emissions by as much as half, as the containers are built from a recyclable multi-layer material. This material absorbs impact and dampens the vibrations from aircraft and trucks that are – along with excursions outside optimal temperature range – a leading cause of in-transit product spoilage. This has led the company to have a verified product loss rate of less than 0.1 per cent.

Nico Ros, CTO and Co-Founder of SkyCell

Pharma clients not only want high quality products and ease of use, but they want the consistency of being able to count on the same supplier. We have received continued interest in frozen temperature control from our existing client base and their logistics partners. We are pleased that we can now offer safe and sustainable solutions in all temperature ranges.

With this new offering, SkyCell now has a container suited to pharmaceutical product transportation at every temperature range, ensuring current and yet-to-be developed vaccines and other lifesaving medicines can reach destinations around the world safely, securely, and with minimal product loss.

Richard Ettl, Ceo and Co-Founder of SkyCell

SkyCell has deep experience in creating safe and efficient pharmaceutical container solutions that protect from temperature excursions, mishandling, and unexpected disruptions in the current environment. We have already seen 60 per cent year-on-year growth in 2020, as pharmaceutical companies and governments around the world recognise the need to ensure their supply chains are robust enough to deliver critical products in viable condition and at sufficient volume.”

Thanks to advanced CAD design and SkyCell technology the containers can store up to five times more energy than traditional solutions, helping to keep the container at a steady temperature for more than 120h. SkyCell is expected to produce 70-100 units of the 1500F container per month, which, for example, could conceivably deliver enough vaccines to vaccinate a country like Switzerland in one month.